Prime Medicine, Inc. Common Stock
Here’s whether Prime Medicine, Inc. Common Stock (PRME) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: strong 1-year return of +141.5%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-6.08% over 10 days); 3-month momentum negative (-22.4%); rising volume on a downtrend (distribution, 1.21x avg). Currently 57.2% off its 52-week high. Score: -4/7.
PRME is trading below its 200-day MA ($3.98) — a key warning sign the longer-term trend is under pressure. An RSI of 32.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +141.5% compares to +27.9% for SPY (beat the market by 113.6%). The current 57.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.